Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769175 | 0.79 | — | — | |
| SCHEMBL22143157 | 0.78 | HTT (0.32) | — | |
| SCHEMBL15484828 | 0.76 | ALDH1A1 (0.43) | CCR1ALDH1A1KMT2A | |
| SCHEMBL9969947 | 0.76 | ALDH1A1 (0.39) | CCR1ALDH1A1KMT2A | |
| SCHEMBL16519510 | 0.74 | LMNA (0.42) | CCR1ALDH1A1KMT2A | |
| SCHEMBL25247969 | 0.72 | NR1H3 (0.58) | ALDH1A1 | |
| SCHEMBL24185801 | 0.72 | NR1H3 (0.41) | ALDH1A1 | |
| SCHEMBL6090782 | 0.72 | PTGS2 (0.36) | — | |
| SCHEMBL4781697 | 0.71 | HTT (0.35) | ALDH1A1KMT2A | |
| SCHEMBL12402447 | 0.71 | SLC2A1 (0.40) | CCR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | CCR1 52/4885ALDH1A1 649/4885KMT2A 2804/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CCR1 52/4885ALDH1A1 649/4885KMT2A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.